Scarica l'app Stockscreener
3.80
3.83%
0.14
Precedente Chiudi:
$3.66
Aprire:
$3.65
Volume 24 ore:
3.85M
Relative Volume:
0.64
Capitalizzazione di mercato:
$1.38B
Reddito:
$2.59M
Utile/perdita netta:
$-137.89M
Rapporto P/E:
-4.6914
EPS:
-0.81
Flusso di cassa netto:
$-69.76M
1 W Prestazione:
-5.00%
1M Prestazione:
-35.26%
6M Prestazione:
+98.95%
1 anno Prestazione:
+150.00%
Intervallo 1D:
$3.64
$3.835
Intervallo di 1 settimana:
$3.6321
$4.08
Portata 52W:
$1.15
$6.75
Atai Beckley N V Stock (ATAI) Company Profile
Nome
Atai Beckley N V
Settore
Industria
Telefono
49 89 2153 9035
Indirizzo
PROF. J.H. BAVINCKLAAN 7, AMSTELVEEN
Confronta ATAI con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ATAI
Atai Beckley N V
|
3.80 | 1.33B | 2.59M | -137.89M | -69.76M | -0.81 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.76 | 107.15B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
755.90 | 77.46B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
436.38 | 58.90B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
918.92 | 56.55B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
198.76 | 42.58B | 447.02M | -1.18B | -906.14M | -6.1812 |
Atai Beckley N V Stock (ATAI) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-10-13 | Iniziato | Needham | Buy |
| 2025-07-29 | Iniziato | Oppenheimer | Outperform |
| 2024-11-18 | Reiterato | H.C. Wainwright | Buy |
| 2024-04-03 | Aggiornamento | Maxim Group | Hold → Buy |
| 2022-11-01 | Iniziato | Loop Capital | Buy |
| 2021-11-30 | Iniziato | Maxim Group | Buy |
| 2021-11-11 | Iniziato | ROTH Capital | Buy |
| 2021-10-18 | Iniziato | H.C. Wainwright | Buy |
| 2021-09-01 | Iniziato | Jefferies | Buy |
| 2021-07-13 | Iniziato | Berenberg | Buy |
| 2021-07-13 | Iniziato | Canaccord Genuity | Buy |
| 2021-07-13 | Iniziato | Cantor Fitzgerald | Buy |
| 2021-07-13 | Iniziato | Citigroup | Buy |
| 2021-07-13 | Iniziato | Cowen | Outperform |
| 2021-07-13 | Iniziato | Credit Suisse | Outperform |
| 2021-07-13 | Iniziato | RBC Capital Mkts | Sector Perform |
| 2021-07-08 | Iniziato | Aegis Capital | Buy |
Mostra tutto
Atai Beckley N V Borsa (ATAI) Ultime notizie
Enhanced (ATAI) overhauls leadership, appoints new CEO, executive chairman and CFO - Stock Titan
Atai Beckley N.V. (ATAI) Receives Buy Rating on BPL-003 Edge against Spravato - MSN
H.C. Wainwright reiterates Buy rating on atai Life Sciences stock By Investing.com - Investing.com Nigeria
H.C. Wainwright reiterates Buy rating on atai Life Sciences stock - Investing.com India
AtaiBeckley to Participate in the Jefferies Global Healthcare Conference in London - The Manila Times
AtaiBeckley (NASDAQ: ATAI) London fireside chat at 11:30 GMT; replay for 90 days - Stock Titan
AtaiBeckley advances clinical pipeline, strengthens balance sheet in Q3 - Proactive financial news
Atai Beckley Q3 Loss Widens, Revenue Rises; Shares Down Pre-Bell - MarketScreener
[8-K] ATAI Life Sciences N.V. Reports Material Event | ATAI SEC FilingForm 8-K - Stock Titan
Atai Beckley N.V. Announces Breakthrough Therapy Designation for BPL-003 and Positive Phase 2 Results for Treatment-Resistant Depression - Quiver Quantitative
Earnings Flash (ATAI) Atai Beckley N.V. Reports Q3 Revenue $749,000 - MarketScreener
Earnings Flash (ATAI) Atai Beckley Posts Q3 Net Loss $0.28 a Share, vs. FactSet Est of $0.11 Loss - MarketScreener
AtaiBeckley Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights - The Manila Times
AtaiBeckley (NASDAQ: ATAI) closes approx. $150M offering, funding into 2029 - Stock Titan
Atai Beckley N.V. (ATAI) Discusses BPL-003 Phase IIb Open-Label Extension Study Results in Treatment Resistant DepressionSlideshow (NASDAQ:ATAI) 2025-11-10 - Seeking Alpha
Atai Beckley Reports Positive Phase 2b Extension Data for Depression Treatment - MarketScreener
Why Atai Life Sciences N.V. (9VC) stock stays undervalued2025 Earnings Impact & Precise Swing Trade Alerts - newser.com
Why Atai Life Sciences N.V. (9VC) stock appears on watchlistsPortfolio Performance Report & Low Drawdown Investment Strategies - newser.com
AtaiBeckley Announces Positive Topline Data from the Phase - GlobeNewswire
Why Atai Life Sciences N.V. (9VC) stock is trending on social media2025 EndofYear Setup & Intraday High Probability Alerts - newser.com
Will Atai Life Sciences N.V. (9VC) stock justify high valuationWeekly Gains Report & Fast Exit Strategy with Risk Control - newser.com
Is Atai Life Sciences N.V. stock poised for growth2025 Earnings Impact & Weekly Market Pulse Updates - newser.com
Is Atai Life Sciences N.V. (9VC) stock nearing a technical breakoutJuly 2025 Macro Moves & Daily Growth Stock Tips - newser.com
Will Atai Life Sciences N.V. stock reach all time highs in 2025Trade Ideas & Safe Capital Preservation Plans - newser.com
ATAI BECKLEY NV Insider Trades - Nasdaq
Published on: 2025-11-08 08:57:18 - newser.com
Is Atai Life Sciences N.V. (9VC) stock trading at attractive multiplesPortfolio Value Report & Stock Portfolio Risk Control - newser.com
ATAI Life Sciences Files Prospectus for Share Resale - MSN
[Form 3] ATAI Life Sciences N.V. Initial Statement of Beneficial Ownership - Stock Titan
Will Atai Life Sciences N.V. stock sustain high P E ratios2025 Market WrapUp & Fast Momentum Stock Entry Tips - newser.com
Atai Beckley N.V.: Target Price Consensus and Analysts Recommendations | ATAI | NL0015000DX5 - MarketScreener
Atai Beckley N.V.: Revenue and Earnings Analysts Forecasts Revisions | ATAI | NL0015000DX5 - MarketScreener
[Form 4] ATAI Life Sciences N.V. Insider Trading Activity - Stock Titan
9VC.SG,0P0001MXOV,0 (9VC.SG) Latest Press Releases & Corporate News - Yahoo! Finance Canada
Combining machine learning predictions for Atai Life Sciences N.V.2025 Growth vs Value & Risk Managed Investment Entry Signals - newser.com
Building trade automation scripts for Atai Life Sciences N.V.July 2025 Summary & Daily Price Action Insights - newser.com
Can Atai Life Sciences N.V. stock resist sector downturnsWeekly Earnings Recap & Expert Approved Trade Ideas - newser.com
Why Atai Life Sciences N.V. stock appeals to dividend seekers2025 Top Decliners & Technical Entry and Exit Alerts - newser.com
Will Atai Life Sciences N.V. stock benefit from upcoming earnings reportsJuly 2025 Breakouts & Community Driven Trade Alerts - Fundação Cultural do Pará
Is Atai Life Sciences N.V. stock a defensive play in 2025Inflation Watch & Real-Time Buy Signal Alerts - newser.com
Chart based analysis of Atai Life Sciences N.V. trendsJuly 2025 Chart Watch & Daily Market Momentum Tracking - newser.com
Latham & Watkins Advises atai Life Sciences in Strategic Combination With Beckley Psytech to Form AtaiBeckley - Legal Desire Media and Insights
Will Atai Life Sciences N.V. (9VC) stock test record highs in 2025Exit Point & AI Driven Price Predictions - newser.com
Atai Beckley files prospectus supplement for resale of 5.3 million shares By Investing.com - Investing.com Nigeria
Watkins Advises atai Life Sciences in Strategic Combination With Beckley Psytech to Form AtaiBeckley - Latham & Watkins
Understanding Atai Life Sciences N.V.’s price movementQuarterly Market Review & Precise Trade Entry Recommendations - newser.com
Is Atai Life Sciences N.V. stock recession proofJuly 2025 Update & Accurate Intraday Trade Tips - fcp.pa.gov.br
Atai Life Sciences N.V. (ATAI) Stock: Sharp Drop Follows Bold Merger Creating AtaiBeckley Biopharma Powerhouse - parameter.io
Why Atai Life Sciences N.V. (9VC) stock could break out in 2025Trade Entry Report & Accurate Intraday Trading Signals - Fundação Cultural do Pará
Atai Beckley files prospectus supplement for resale of 5.3 million shares - Investing.com Australia
Atai Beckley N V Azioni (ATAI) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.38%
1.42%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):